Global medical communications play a crucial role in successful product launches and health education strategies. A phrase that reassures clinicians in Germany may alarm those in Japan. A regulatory-approved claim in the United States might be non-compliant in the European Union.
As pharmaceutical and medtech companies aim to expand globally, medical content localisation becomes essential to maintain scientific accuracy, cultural relevance and regulatory compliance.
At Elion, we see how well-adapted content can directly influence engagement and outcomes across diverse markets.
Why localisation matters in global communications
Cross-cultural medical communication goes beyond simply translating materials. It ensures that medical content is interpreted correctly within the clinical, cultural and linguistic context of each audience. In its Public Health guide, the European Centre for Disease Prevention and Control (ECDC) advises on aligning language and health literacy to improve patient understanding and adherence.
In global medical communications, terminology, tone and framing of risk influence how audiences receive or interpret messages. In this regard, cultural context is vital: it guides adaptation to different markets, either through the required level of detail of the information, the format of presentation or contextual explanations.
Practical examples highlight these challenges. For instance, visual elements such as colours and images can carry different meanings across cultures. Although the colour white expresses purity in Western contexts, it is often a symbol of mourning in parts of Asia.
Differences in health literacy determine how audiences comprehend medical information. In regions with low health literacy, simple language or contextual explanations can improve understanding, while complex clinical terminology or dense numerical data may reduce it.
Cultural context also influences how audiences perceive risk. For example, gaps in health literacy have been linked to misinterpretation of medical risk information in certain populations, contributing to inappropriate medicine use in real-world settings. A report from 2013 in Brazil demonstrated that many pregnant women continued using thalidomide, a drug that treats leprosy symptoms but infamously causes birth defects. This example reflects the challenges in effectively communicating risks to patients, particularly in remote areas with limited access to health information.
Content localisation in healthcare also plays a role in equity. The World Health Organization (WHO) highlights that accessible and culturally appropriate health information is fundamental to improving global health outcomes. For pharmaceutical and biotech companies, this means integrating localisation early to build content that can adapt.
Overcoming the challenges of multilingual communications
Although fluency is a prerequisite for multilingual medical writing, it is only the starting point. Even well‑written translations fall short without therapeutic expertise, cultural awareness and knowledge of local communication norms. Teams often rely on literal or AI‑based translations, but these can miss clinical nuance, context and message intent.
How can pharma and medtech companies overcome the challenges associated with multilingual communications?
A structured, evidence-based approach to content localisation is essential. Guidance from the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) emphasises the importance of combining linguistic accuracy with cultural and clinical validation to ensure high-quality multilingual medical writing. Recommended practices include:
- working with local experts and medical translators with therapeutic expertise
- using forward and back-translation to verify accuracy and preserve intent
- conducting linguistic validation to ensure clarity, consistency and cultural relevance
- testing materials with target audiences to confirm comprehension
- adapting content for region-specific communication channels, including preferred digital platforms and social media.
Regulatory diversity in medical communications
Regulatory variation remains one of the most complex challenges in global medical communications. Agencies such as the European Medicines Agency (EMA), the US Food and Drug Administration (FDA) and the Japan Pharmaceuticals and Medical Devices Agency (PMDA) define distinct requirements for how to develop and publish medical and promotional content.
These differences extend beyond terminology. They offer guidance on presenting clinical data, communicating safety information and referencing claims. Some regions, such as the European Union and the United Kingdom, have strict regulations regarding the distinction between promotional and non-promotional content; others impose specific requirements on audience targeting.
Regulatory differences are particularly evident in approaches to direct-to-consumer (DTC) communication. For example, the United States and New Zealand permit DTC advertising of prescription medicines, whereas most other regions restrict such communication to healthcare professionals.
At Elion, we support global teams by combining regulatory awareness with strategic content development. We work closely with global and local stakeholders to develop medical communications that maintain scientific integrity and meet local requirements. Our objective is to help clients move efficiently from global strategy to local execution.
Preparing for a global launch: From theory to practice
Translating medical insight into execution calls for a structured approach. Pharma and medtech organisations can begin by developing a core global messaging framework based on scientific evidence and value propositions. This framework serves as a foundation that can adapt to local markets to reflect regulatory requirements, cultural expectations and audience needs.
For example, a global campaign may present consistent clinical data across regions, while tailoring tone, imagery and risk communication to align with local norms. Similarly, messaging approved for healthcare professionals in one market may need to be adapted for patient-facing use in another. Such approaches maintain consistency and ensure relevance and compliance across markets.
Conclusion
Adapting medical content for global audiences requires more than translation; it demands scientific precision, cultural awareness and regulatory insight. Health content localisation ensures that content is not only compliant, but also meaningful and impactful across markets, languages and cultures. For pharmaceutical and medtech organisations operating internationally, localisation is a central component of successful communication strategies.
Planning a global launch? Let’s talk about how our Elion team can tailor your medical communications to resonate on a global level.
Photo credit: Image courtesy of Magnific
